Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort.
Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, Schoenfeld JD, Singhal A, Park W, Cowzer D, Harrold E, Varghese AM, El Dika I, Crane C, Harding JJ, Abou-Alfa GK, Kingham TP, Wei AC, Yu KH, D'Angelica MI, Balachandran VP, Drebin J, Jarnagin WR, Bandlamudi C, Kelsen D, Capanu M, Soares KC, Balogun F, O'Reilly EM. Keane F, et al. Among authors: crowley f. J Natl Cancer Inst. 2024 Oct 26:djae269. doi: 10.1093/jnci/djae269. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39460946
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.
D'Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, Slater S, Fulgenzi CAM, Celsa C, Manfredi GF, Pai M, Goldin RD, Ward SC, Fiel MI, Shu DH, Su YY, Cortellini A, Baretti M, Anders R, Yarchoan M, Hsu C, Marron TU, Pinato DJ. D'Alessio A, et al. Among authors: crowley f. Lancet Oncol. 2024 Nov;25(11):1465-1475. doi: 10.1016/S1470-2045(24)00457-1. Epub 2024 Oct 19. Lancet Oncol. 2024. PMID: 39437804 Free article.
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Nassar AH, et al. Among authors: crowley f. J Thorac Oncol. 2024 Sep 10:S1556-0864(24)02265-2. doi: 10.1016/j.jtho.2024.09.1379. Online ahead of print. J Thorac Oncol. 2024. PMID: 39260522
28 results